AML
News
FDA panel not ready to recommend quizartinib approval for FLT3-ITD+ AML
SILVER SPRING, MD. – A small clinical benefit, questions about the validity of the data, and concerns about cardiovascular adverse events point to...
Conference Coverage
Master trial seeks to aid drug development for pediatric AML
NEW ORLEANS – “What we see in childhood AML is a lot different than what we see in adult AML, and this challenges the paradigm that we have...
Conference Coverage
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
Conference Coverage
Combo proves most effective in HMA-naive, higher-risk MDS
NEWPORT BEACH, CALIF. – Oral rigosertib plus azacitidine produced a 90% response rate in higher-risk patients with myelodysplastic syndromes who...
News
FDA approves ivosidenib frontline for certain AML patients
The expanded approval means that ivosidenib can be used first-line for acute myeloid leukemia patients with an IDH1 mutation who are not eligible...
Conference Coverage
Sorafenib plus GCLAM held safe in AML, MDS phase-1 study
NEWPORT BEACH, CALIF. – Sorafenib plus GCLAM has shown promise in a phase 1 trial of patients with AML and MDS.
Conference Coverage
Study highlights lack of data on transgender leukemia patients
NEWPORT BEACH, CALIF. – Researchers identified transgender leukemia patients by detecting gender-karyotype mismatches.
Video
ALF 2019 showcases evolving treatment of AML
NEWPORT BEACH, CALIF. – Dr. Martin Tallman discusses meeting presentations on the treatment of AML.
Conference Coverage
Back to the drawing board for MPN combo
NEWPORT BEACH, CALIF. – Ruxolitinib plus decitabine won’t proceed to a phase 3 trial for the treatment of accelerated or blast phase...
Video
Gilteritinib prolonged survival in FLT3-mutated AML
Patients with acute myeloid leukemia and FLT3-activating mutations are at increased risk for early relapse and poor overall survival.
Conference Coverage
Whole-genome sequencing demonstrates clinical relevance
GLASGOW – A study comparing whole-genome sequencing (WGS) with fluorescence in situ hybridization showed that the WGS was reliable and clinically...